title: Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US.
abstract: OBJECTIVE
  Guidelines support clopidogrel therapy in medically-treated or percutaneous coronary intervention (PCI) patients after hospitalization for acute coronary syndrome (ACS). However, clopidogrel discontinuation has been associated with increased short-term risks. This study evaluated the risk of adverse outcomes (AOs), defined as death or recurrent ACS, after clopidogrel discontinuation in a managed-care population.
  
  
  METHODS
  ACS patients (n = 7625) with ≥1 clopidogrel pharmacy claim from 2001 to 2006 and no AO before discontinuing clopidogrel were identified from administrative claims data. AO occurrences were recorded at 90-day intervals following clopidogrel discontinuation.
  
  
  RESULTS
  The mean (SD) duration of clopidogrel therapy for medically-treated, bare metal stent (BMS) and drug eluting stent (DES) patients was 349.2 (393.1) days, 235.6 (383.0) days, and 280.2 (227.1) days, respectively. Among medically-treated patients, Poisson regression analysis showed a 2.19 times higher AO risk (p < 0.01), a 1.63 times greater risk among BMS patients (p < 0.01), and a 1.56 times greater risk for DES patients (p ≥ 0.05) during days 0-90 versus days 91-180 after clopidogrel discontinuation. Sensitivity analysis showed that medically-treated, BMS and DES patients with ≤90 days of clopidogrel therapy had 2.13, 1.68 and 2.40 times higher AO risk, respectively, during days 0-90 versus 91-180 after discontinuation. No significant elevated AO risk was observed after discontinuation in patients on clopidogrel for 91-270 days. Limitations included those associated with the use of administration claims date, the absence of clinical data and lack of knowledge of aspirin use.
  
  
  CONCLUSIONS
  Patients who discontinued clopidogrel therapy were at high risk of death or recurrent ACS during the first 90 days. AO risks following discontinuation appeared elevated in patients with ≤90 days of clopidogrel therapy versus those with >90 days of treatment.
authors: HealthCore, Inc., Wilmington, DE 19801, USA. jstephenson@healthcore.com
authors: Judith J
authors: JJ
authors: Stephenson
authors: Chun-Lan
authors: CL
authors: Chang
authors: Gail
authors: G
authors: Devecchis Wygant
authors: Ole
authors: O
authors: Hauch
authors: Mark J
authors: MJ
authors: Cziraky
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000401:mortality*; D000368:Aged; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D015994:Incidence; D019458:Insurance Coverage; D007348:Insurance, Health; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016012:Poisson Distribution; D012189:Retrospective Studies; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine